zika
viru
zikv
emerg
mosquitoborn
flaviviru
spread
countri
worldwid
sinc
despit
activ
research
current
licens
vaccin
therapeut
previous
report
develop
variou
adenovir
vector
vaccin
candid
zikv
abil
stimul
effect
immun
mice
provid
protect
upon
zikv
challeng
model
use
nonadjuv
singl
vaccin
approach
studi
construct
variou
modifi
vaccinia
ankara
mva
virus
express
zikv
envelop
e
modif
precursor
membran
prm
cterminu
envelop
transmembran
domain
tm
similar
vaccin
candid
mvazikv
vaccin
candid
evalu
nonadjuv
singl
vaccin
regimen
zikv
brazilian
isol
use
viraemia
correl
protect
report
induct
modest
level
antizikv
e
antibodi
mva
vector
vaccin
suboptim
efficaci
zikv
challeng
model
result
indic
requir
addit
strategi
use
mvazikv
vaccin
afford
steril
protect
upon
nonadjuv
singl
vaccin
regim
zika
viru
zikv
mosquitoborn
flaviviru
viru
belong
famili
flavivirida
first
discoveri
sentinel
rhesu
monkey
uganda
zikv
caus
sporad
outbreak
africa
south
asia
occurr
major
outbreak
micronesia
french
polynesia
zikv
spread
rapidli
throughout
america
sinc
first
report
brazil
affect
countri
worldwid
zikv
classifi
two
lineag
african
af
asian
asian
lineag
caus
current
outbreak
occur
worldwid
main
vector
urban
transmiss
zikv
aed
mosquito
although
sexual
contact
vertic
transmiss
also
respons
viru
dissemin
infect
zikv
associ
neurolog
complic
microcephali
foetus
syndrom
gb
adult
consid
congenit
zika
syndrom
cz
consider
progress
research
vaccin
therapeut
zikv
howev
licens
vaccin
yet
avail
zikv
mani
zikv
vaccin
candid
inactiv
viru
base
dna
mrna
recombin
viral
vector
encod
precursor
membran
prm
envelop
e
zikv
protein
current
phase
ii
clinic
trial
modifi
vaccinia
viru
ankara
mva
extens
studi
vectoredvaccin
variou
infecti
diseas
reach
clinic
trial
regard
safe
cost
effect
efficaci
vaccin
vector
previous
report
develop
four
zikv
vaccin
candid
protect
efficaci
homolog
zikv
challeng
model
four
zikv
vaccin
candid
prme
prme
env
env
shown
stimul
product
anti
zikv
antibodi
demonstr
protect
efficaci
homolog
zikvlineag
challeng
model
vaccin
candid
contain
prme
delet
transmembran
domain
prme
induc
highest
titr
antienvelop
zikv
antibodi
provid
efficaci
zikv
infect
singl
nonadjuv
vaccin
describ
develop
mvazikv
vaccin
candid
base
asian
lineag
sequenc
previou
vaccin
candid
mvazikv
vaccin
induc
modest
level
antizikv
envelop
antibodi
measur
week
week
postimmunis
zikv
mice
challeng
model
two
mvazikv
vaccin
candid
env
prme
provid
best
yet
partial
protect
zikv
shown
reduct
level
viraemia
balbc
mice
rest
mva
candid
offer
lower
degre
reduct
viral
load
mice
studi
report
mva
zikv
vaccin
candid
may
limit
candid
clinic
assess
use
singlevaccin
approach
gener
mvabas
zikv
vaccin
candid
subclon
zikv
transgen
prme
prme
env
env
parent
mva
plasmid
figur
transfect
aatiirestrict
enzym
linearis
mvazikv
plasmid
mva
particl
extract
purifi
dna
extract
purifi
mva
vaccin
carri
verifi
correct
transgen
dna
length
correct
gener
mvazikv
vaccin
candid
verifi
pcr
use
flank
region
primer
primer
tkr
confirm
integr
transgen
within
mvazikv
genom
figur
ensur
viral
prepar
satisfactori
test
mvazikv
vaccin
candid
express
prme
neg
stain
transmiss
electron
microscopi
tem
confirm
brickshap
morpholog
size
nm
nm
expect
mva
vector
describ
elsewher
figur
express
zikv
immunogen
confirm
western
blot
cell
extract
mvazikvtransduc
cell
use
antizikv
e
primari
antibodi
figur
taken
togeth
show
mva
viral
vector
correctli
packag
carri
zikv
transgen
genom
importantli
capabl
induc
express
zikv
e
transduc
cell
assess
immunogen
mvazikv
vaccin
candid
monitor
antizikv
e
antibodi
titr
week
week
nonadjuv
singl
intramuscular
vaccin
immunis
balbc
mice
n
enzymelink
immunosorb
assay
elisa
four
week
postimmunis
mvazikv
vaccin
candid
induc
product
antizikv
e
antibodi
antibodi
increas
trend
group
vaccin
lack
e
transmembran
domain
tm
figur
timepoint
mva
env
induc
highest
level
antibodi
mean
endpoint
titr
week
postprim
immunis
amount
antizikv
e
titr
elicit
mva
vaccin
candid
show
nonstatist
signific
increas
vaccin
group
prme
group
highest
mean
log
reciproc
titr
figur
antizikv
e
antibodi
sera
group
neg
measur
timepoint
furthermor
assess
cellular
respons
isol
peripher
blood
mononuclear
cell
pbmc
elicit
mvazikv
vaccin
candid
four
week
postimmunis
enzymelink
immunospot
elispot
assay
show
three
six
balbc
mice
receiv
mva
prme
induc
modest
cell
respons
mean
spot
form
unit
sfu
pbmc
rest
vaccin
candid
induc
smaller
amount
cell
respons
mean
pbmc
taken
togeth
mvazikv
vaccin
immunogen
balbc
mice
humor
respons
remain
similar
week
singl
vaccin
dose
wherea
low
level
cellular
respons
detect
week
postimmunis
assess
efficaci
mvazikv
vaccin
candid
balbc
mice
fourweek
postimmunis
n
intraven
challeng
zikv
strain
brazil
zikvbr
previous
describ
vaccin
efficaci
measur
partial
complet
reduct
viremia
retrotranscriptas
rt
quantit
polymeras
chain
reaction
qpcr
post
zikv
challeng
figur
control
group
challeng
zikv
display
expect
viraemia
kinet
compris
viral
load
peak
day
clearanc
viraemia
day
figur
panel
mice
vaccin
singl
dose
mvazikv
vaccin
confer
partial
protect
zikv
challeng
mva
prme
vaccin
group
mice
reduc
viral
load
blood
reduc
viral
load
peak
detect
three
five
mice
two
mice
present
viral
load
peak
day
instead
day
viral
peak
mice
drop
viral
load
day
clear
viru
day
mice
receiv
mva
prme
vaccin
reflect
lower
viraemia
three
five
mice
wherea
two
mice
show
viraemia
similar
control
group
similar
trend
observ
mva
vaccin
express
e
mvaenv
interestingli
mva
vaccin
express
e
without
tm
domain
mva
env
improv
protect
efficaci
comparison
rest
vaccin
group
besid
protect
efficaci
mva
env
better
rest
mvazikv
vaccin
substanti
reduc
zikv
load
blood
protect
reach
efficaci
detect
statist
signific
mvazikv
vaccin
group
analys
threeday
post
challeng
viral
load
figur
taken
togeth
conclud
singl
dose
nonadjuv
vaccin
mvazikv
vaccin
elicit
humor
immunogen
vaccin
could
afford
steril
protect
balbc
mice
challeng
zikv
zikv
vaccin
target
product
profil
indic
prefer
dose
regimen
zika
vaccin
develop
singl
immunis
although
minim
requir
one
dose
still
possibl
howev
challeng
remain
ensur
protect
efficaci
primeboost
regimen
use
short
vaccin
interv
ad
burden
duplic
administr
cost
deliveri
dose
storag
etc
week
zikv
vaccin
target
product
profil
indic
prefer
dose
regimen
zika
vaccin
develop
singl
immunis
although
minim
requir
one
dose
still
possibl
howev
challeng
remain
ensur
protect
efficaci
primeboost
regimen
use
short
vaccin
interv
ad
burden
duplic
administr
cost
deliveri
dose
storag
etc
previous
demonstr
nonrepl
adenoviralvector
vaccin
express
zikv
antigen
induc
high
level
immun
protect
efficaci
zikv
mice
challeng
model
zikvbr
strain
upon
adjuv
singl
adenoviralbas
vaccin
explor
suitabl
differ
viralvector
platform
adenoviralvector
vaccin
modifi
vaccinia
ankara
mva
viru
engin
express
antigen
previous
express
adenoviralvector
vaccin
rational
behind
construct
mva
vectoredzikv
vaccin
reli
proven
safeti
clinic
trial
high
immunogen
demonstr
variou
vaccin
develop
furthermor
et
al
construct
mvazikv
vaccin
express
prme
gene
capabl
express
viruslik
particl
vlp
induc
partial
protect
mice
zikv
challeng
upon
homolog
primeboost
approach
particular
interest
mva
vaccin
express
nonstructur
protein
zikv
demonstr
effect
singleor
twodos
vaccin
develop
four
mvazikv
vaccin
express
envelop
gene
without
transmembran
domain
presenc
absenc
prm
antigen
hand
use
mva
effici
counterpart
mvazikv
vaccin
candid
induc
modest
level
antizikv
e
antibodi
singl
vaccin
approach
fail
confer
steril
protect
observ
agre
perez
et
al
singl
immunis
mvazikv
induc
log
reduct
viraemia
wherea
twodos
immunis
decreas
viral
load
steril
protect
achiev
data
highlight
follow
consider
suboptim
protect
observ
studi
might
improv
booster
vaccin
provid
elicit
antizikv
antibodi
key
confer
steril
protect
need
improv
vaccin
dose
deliveri
take
consider
interv
vaccin
mount
maintain
longlast
respons
zikv
aim
develop
protect
vaccin
given
singl
administr
conclud
mvazikv
vaccin
ensur
full
protect
efficaci
howev
would
interest
assess
twodos
regimen
particularli
mva
env
vaccin
perform
best
control
viraemia
furthermor
would
interest
test
combinatori
primeboost
strategi
mvazikv
vaccin
ie
prime
mvaprm
follow
booster
mva
env
object
assess
best
combin
could
improv
result
observ
us
other
studi
use
balbc
mous
strain
lethal
outcom
upon
zikv
infect
henc
measur
vaccin
efficaci
mean
partial
complet
reduct
viraemia
rtqpcr
howev
studi
use
highli
suscept
zikv
challeng
model
mice
would
help
explor
zikv
presenc
key
organ
brain
spleen
reproduct
tract
given
level
efficaci
mvazikv
vaccin
prevent
viraemia
expect
zikv
viral
load
may
found
organ
lastli
mva
vaccin
shown
remark
effici
given
heterolog
boost
therefor
vaccin
given
primeboost
regimen
could
consid
increas
level
neutralis
antibodi
zikv
although
prme
vaccin
shown
elicit
function
longlast
antibodi
month
month
singl
immunis
inbr
outbr
mice
respect
variou
zikv
vaccin
platform
base
zikv
envelop
report
consist
dna
mrna
vlp
adenovir
vector
mva
use
differ
rout
administr
therefor
level
immunogen
zikv
neutralis
vivo
efficaci
outcom
still
good
standard
assess
vaccin
develop
result
provid
valuabl
inform
toward
develop
efficaci
vaccin
develop
could
prevent
futur
zikv
outbreak
femal
inbr
balbc
mice
use
assess
immunogen
zikv
challeng
mice
purchas
either
envigo
bicest
uk
charl
river
wilmington
usa
anim
procedur
use
accord
term
uk
home
offic
anim
act
project
licens
immunis
immunogen
procedur
approv
univers
oxford
anim
care
ethic
review
committe
anim
experi
perform
harvard
immunis
zikv
challeng
approv
bidmc
institut
anim
care
use
committe
iacuc
transgen
design
base
asian
lineag
produc
geneart
prme
geneart
prme
plasmid
use
templat
gener
four
zikv
antigen
prme
prme
env
env
previous
describ
zikv
antigen
use
gener
mva
virus
previous
describ
briefli
result
antigen
sequenc
ligat
shuttl
vector
pmvagfp
place
open
read
frame
orf
control
vaccinia
earlyl
promot
also
includ
gfp
marker
gene
control
vaccinia
late
promot
shuttl
vector
transfect
chicken
embryo
fibroblast
cef
infect
mva
homolog
recombin
insert
zikv
orf
gfp
marker
gene
tk
locu
mva
infect
cell
harvest
screen
pcr
confirm
ident
plaqu
pick
perform
cultur
free
parent
viru
determin
pcr
recombin
virus
plaqu
purifi
expand
cell
prepar
mva
vaccin
stock
perform
infect
permiss
cef
cell
low
multipl
infect
moi
supernat
collect
remain
cell
lyse
success
round
freez
thaw
releas
viru
concentr
centrifug
wv
sucros
cushion
titr
determin
routin
plaqu
assay
cell
monolay
formvarcarbon
mesh
cu
grid
glowdischarg
air
load
mva
viral
sampl
encod
prme
excess
liquid
remov
grid
wash
three
time
milliq
water
final
grid
treat
uranyl
acet
excess
uranyl
acet
care
remov
use
filter
paper
grid
air
dri
analys
transmiss
electron
microscop
fei
eindhoven
netherland
test
express
zikv
antigen
cell
transfect
rmva
h
transfect
cell
extract
test
western
blot
previous
describ
briefli
sampl
ad
laemmli
sampl
buffer
contain
mm
boil
min
load
miniprotean
tgx
protein
gel
biorad
precis
plu
protein
tm
westernc
tm
standard
protein
transfer
onto
nitrocellulos
membran
biorad
transblot
turbo
tm
membran
block
skim
milk
pb
tween
pbst
h
incub
antizika
env
monoclon
antibodi
mous
mab
zika
env
protein
aalto
bioreag
dublin
republ
ireland
wash
pbst
membran
incub
h
appropri
secondari
antibodi
use
hrpconjug
goat
antimous
igg
biorad
cat
membran
wash
incub
chemiluminesc
substrat
clariti
tm
western
ecl
blot
substrat
biorad
watford
uk
prior
detect
signal
chemiluminesc
western
blot
imag
system
imag
lab
biorad
group
five
six
mice
vaccin
singl
dose
new
recombin
modifi
vaccinia
ankara
mva
encod
zikv
antigen
dose
pfu
viral
vector
vaccin
administ
intramuscularli
im
dilut
endotoxinfre
pb
enzymelink
immunosorb
assay
elisa
recombin
zikv
envelop
protein
use
measur
antizikv
envelop
antibodi
concentr
vaccin
mice
elisa
previous
describ
briefli
nunc
maxisorp
immuno
elisa
plate
coat
zika
viru
envelop
antigen
dilut
pb
final
concentr
left
room
temperatur
rt
overnight
plate
wash
six
time
tween
pbst
block
piercetm
proteinfre
pb
block
buffer
thermo
fisher
scientif
waltham
usa
h
rt
mice
sera
obtain
week
week
singl
immunis
mvazikv
vaccin
mice
sera
reactiv
zikv
e
serial
dilut
threefold
pbst
per
well
final
volum
incub
h
rt
follow
wash
six
time
pbst
bound
antibodi
detect
follow
h
incub
alkalin
phosphataseconjug
antibodi
specif
whole
mous
igg
sigma
aldrich
st
loui
mo
usa
follow
six
wash
pbst
develop
achiev
use
dilut
diethanolamin
buffer
absorb
valu
measur
analys
use
clariostar
instrument
bmg
labtech
aylesburi
gb
serum
antibodi
endpoint
titr
defin
sera
dilut
reach
greater
valu
averag
valu
control
sera
plu
three
standard
deviat
elispot
carri
use
peripher
blood
mononuclear
cell
pbmc
isol
blood
previous
describ
briefli
maip
elispot
plate
millipor
coat
antimous
mab
contain
mous
elispot
basic
alp
kit
ref
h
block
complet
dmem
media
fc
isol
pbmc
use
ack
buffer
solut
plate
alongsid
specif
peptid
overlap
aa
splenocyt
per
well
h
incub
cell
discard
plate
wash
pb
follow
biotinyl
antimous
mab
pb
ad
well
incub
h
wash
plate
incub
alp
pb
reagent
h
anoth
wash
step
develop
solut
biorad
watford
uk
use
spot
visibl
reaction
stop
wash
plate
water
spot
acquir
use
elispot
reader
spot
form
cell
sfc
pbmc
produc
calcul
zikv
challeng
perform
describ
briefli
vaccin
balbc
mice
n
per
group
infect
week
four
intraven
iv
rout
viral
particl
plaqueform
unit
pfu
zikvbr
strain
viral
load
follow
zikv
challeng
quantit
rtpcr
day
sampl
size
determin
achiev
power
detect
signific
differ
protect
efficaci
vaccin
administ
blind
experi
experiment
outcom
zikv
challeng
sampl
decod
viral
load
assess
describ
briefli
rna
extract
serum
qiacub
ht
qiagen
germantown
usa
rna
purifi
use
rna
clean
concentr
kit
zymo
research
irvin
usa
rna
qualiti
concentr
assess
bidmc
molecular
core
facil
harvard
univers
log
dilut
rna
standard
reversetranscrib
includ
rtpcr
assay
viral
load
calcul
viru
particl
per
ml
assay
sensit
copi
per
ml
infect
viru
peripher
blood
zikv
challeng
mice
confirm
pfu
assay
specif
primer
use
amplifi
region
contain
capsid
zikv
genom
